Kura Oncology, Inc. (KURA)
KURA moved a median of -0.13% 30 minutes after news, and -0.90% by the close. How KURA actually reacts to news — the realized, point-in-time move the market made, measured across 368 labeled events over the last three years with zero look-ahead.
KURA’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.12% | 46% | 367 |
| 30-min | -0.13% | 49% | 367 |
| 60-min | +0.09% | 53% | 368 |
| to close | -0.90% | 38% | 365 |
| Middle 50% of KURA reactions | -1.59% to +1.68% |
|---|---|
| Median reaction (30-min) | -0.13% |
| Measured reactions | 368 |
Half of all Kura Oncology, Inc. news events land between -1.59% and +1.68% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How KURA reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 15 | -0.43% | 47% | -0.69% |
| Analyst downgrades | 14 | -0.39% | 36% | +0.54% |
| Coverage initiations | 14 | -1.43% | 43% | -0.01% |
| Rating reiterations | 114 | -0.23% | 40% | -0.39% |
| Price-target cuts | 11 | +0.44% | 64% | +1.01% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 1 further class was observed with fewer than 10 measured events and is not published. See how KURA ranks against every other measured name →
That’s how KURA usually reacts — get an email when it moves on news →Email me when KURA moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to KURA's baseline. Nothing else.
Recent KURA events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes | Press release | GlobeNewswire | -0.68% | -4.47% | |
| Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes | Press release | GlobeNewswire | -0.29% | +2.30% | |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.92% | -1.84% | |
| Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes | Press release | GlobeNewswire | -0.33% | +1.46% | |
| Form 8-K Kura Oncology, Inc. For: Sep 09 | SEC filing · Form 8-K | SEC EDGAR | -0.56% | -3.28% | |
| Kura Oncology Launches Caspian Therapeutics with $50 Million Financing to Advance Menin Inhibition as a Potential Disease-Modifying Approach for Diabetes | Press release | GlobeNewswire | -0.56% | -3.28% | |
| Form 8-K Kura Oncology, Inc. For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -2.10% | -2.72% | |
| Kura Oncology Appoints Jennifer Fulk as Chief Financial Officer | Press release | GlobeNewswire | -2.10% | -2.72% | |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.39% | +2.40% | |
| Kura Oncology to Participate in Three Investor Conferences in September | Press release | GlobeNewswire | +0.16% | +2.79% | |
| Form 10-Q Kura Oncology, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +6.00% | -5.35% | |
| Form 8-K Kura Oncology, Inc. For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +6.00% | -5.35% | |
| Kura Oncology Reports Second Quarter 2026 Financial Results | Press release | GlobeNewswire | +6.00% | -5.35% | |
| Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity | Press release | GlobeNewswire | +0.53% | — | |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.21% | +2.13% | |
| Kura Oncology to Report Second Quarter Financial Results | Press release | GlobeNewswire | +1.38% | -2.33% | |
| Form 8-K Kura Oncology, Inc. For: Jul 24 | SEC filing · Form 8-K | SEC EDGAR | +2.35% | +4.14% | |
| Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 | Press release | GlobeNewswire | -1.68% | -5.32% | |
| Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026 | Press release | GlobeNewswire | -0.73% | +2.56% | |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | -0.86% | -0.18% | |
| Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML | Press release | GlobeNewswire | -0.75% | +1.72% | |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.63% | -0.23% | |
| Form 8-K Kura Oncology, Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | +0.63% | -0.23% | |
| Form S-8 Kura Oncology, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.63% | -0.23% | |
| Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy | Press release | GlobeNewswire | -1.90% | -3.30% | |
| Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML | Press release | GlobeNewswire | -1.87% | -1.21% | |
| Form DEFA14A Kura Oncology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | -0.86% | -1.63% | |
| Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors | Press release | GlobeNewswire | -0.44% | -8.20% | |
| Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit | Press release | GlobeNewswire | +1.34% | +15.14% | |
| Form 10-Q Kura Oncology, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.45% | +5.69% | |
| Form 8-K Kura Oncology, Inc. For: May 12 | SEC filing · Form 8-K | SEC EDGAR | +0.45% | +5.69% | |
| Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress | Press release | GlobeNewswire | -1.26% | +1.36% | |
| Kura Oncology Reports First Quarter 2026 Financial Results | Press release | GlobeNewswire | +0.45% | +5.69% | |
| Kura Oncology to Participate in Bank of America Securities Healthcare Conference | Press release | GlobeNewswire | -0.24% | +2.25% | |
| Kura Oncology to Report First Quarter 2026 Financial Results | Press release | GlobeNewswire | -0.54% | -0.54% | |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.56% | +3.70% | |
| Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib | Press release | GlobeNewswire | +2.32% | +1.79% | |
| Form ARS Kura Oncology, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +0.92% | +0.23% | |
| Form DEF 14A Kura Oncology, Inc. For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +0.92% | +0.23% | |
| Form DEFA14A Kura Oncology, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.92% | +0.23% | |
| Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026 | Press release | GlobeNewswire | -1.37% | +1.03% | |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +0.12% | -1.39% | |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +3.50% | +8.21% | |
| Form 10-K Kura Oncology, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -1.39% | +7.31% | |
| Form 8-K Kura Oncology, Inc. For: Mar 05 | SEC filing · Form 8-K | SEC EDGAR | -1.39% | +7.31% | |
| Kura Oncology Reports Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -1.39% | +7.31% | |
| Kura Oncology to Report Fourth Quarter and Full Year 2025 Financial Results | Press release | GlobeNewswire | -1.56% | +0.82% | |
| Kura Oncology to Participate in Three Upcoming Investor Conferences | Press release | GlobeNewswire | +1.42% | +1.18% | |
| Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +2.52% | +3.85% | |
| Form 8-K Kura Oncology, Inc. For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | +2.35% | +0.49% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the KURA section they belong to.
Where else KURA is measured.
KURA earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MIRAGEN THERAPEUTICS INC (MGEN) | 369 | -0.39% | 39% |
| Penumbra, Inc. (PEN) | 369 | +0.06% | 60% |
| Arcus Biosciences, Inc. (RCUS) | 368 | -0.09% | 45% |
| Ligand Pharmaceuticals Incorporated (LGND) | 367 | +0.06% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Kura Oncology, Inc.'s median reaction calculated?
Every labeled KURA news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 368 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 49% of KURA's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does KURA's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.